Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 29;28(9):1872–1882. doi: 10.1038/s41591-022-01916-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 6 — a, Definition of the Immunosign 21 score cutoff. The Immunosign 21 scoring function is an algorithm derived from the Immunoscore algorithm, is independent of clinical outcome, and is predefined as the 25th percentile of the observed scores among samples. b-d, Correlation of Immunosign 21 (low versus high) with cell subsets in 3 independent datasets (Two-sided Wilcoxon test). b,c, Immunosign 21 correlations with cell subset densities analysed by Immunoscore TCE/TCE+ panels in b, ZUMA-1 pretreatment tumour biopsy specimens from third line, r/r DLBCL patients (subset 1, n = 22 for T-cell subsets; n = 15 for myeloid subsets) and c, DLBCL biopsy specimens at diagnosis from treatment-naïve patients (n = 67). d, Immunosign 21 correlations with normalised gene expression of T-cells or of myeloid cells analysed by IO360 NanoString panel in pretreatment tumour biopsy specimens from second line DLBCL patients (n = 252). The number of samples per group is indicated on each panel. DLBCL, diffuse large B-cell lymphoma; FOXP3, forkhead box P3; LAG-3, lymphocyte-activation gene 3; M-MDSC, monocytic myeloid-derived suppressor cell; PD-1, programmed cell death protein 1; PMN-MDSC, polymorphonuclear myeloid-derived suppressor cell; SC, Suppressive cell; TCE, T-cell Exhaustion; TIM-3, T-cell immunoglobulin and mucin domain 3; Treg, regulatory T-cell.